Scholarlink

Background <p>Glioblastoma is the most common malignant brain tumor, with extremely poor prognosis, and patient’s T cells are exhausted, dysfunctional, and unable to eliminate Glioblastoma. To our knowledge, there is no effective and safe treatment for rejuvenating and improving multiple functions of exhausted T cells. We previously found that specific Neurotransmitters and Neuropeptides induce direct, potent and beneficial effects on human T cells.</p> Method <p>We studied if Dopamine, Glutamate, GnRH-II, Neuropeptide Y or their combinations, can rejuvenate and improve peripheral T cells of four Glioblastoma patients.</p> Results <p>The Glioblastoma patients had abnormally low numbers of T cells, and mostly small T cells. Single Ex-vivo treatment (24&#xa0;h) of Glioblastoma patient’s T cells with either Dopamine, Glutamate, GnRH-II, or Neuropeptide Y, or their combinations (10<sup>−8</sup>&#xa0;M, without any antigen/mitogen/cytokine/growth factor), induced multiple beneficial effects: 1. increased the number of live T cells; 2. decreased simultaneously all tested exhaustion-related immune checkpoint inhibitors: PD-1, Tim-3, LAG-3, TIGIT and CD160; 3. increased expression of TCR-associated CD3zeta; 4. increased proliferation of patient’s T cells in response to human Glioblastoma cells; and 5. dramatically increased arrest of Glioblastoma cells by Glioblastoma patient’s T cells.</p> Conclusions <p>Dopamine, Glutamate, Neuropeptide Y or GnRH-II, and the most beneficial being Dopamine + Neuropeptide Y, and Glutamate + Neuropeptide Y, can rejuvenate and improve Glioblastoma patient’s T cells. They simultaneously decrease multiple immune checkpoint imhibitory receptors, and increase CD3zeta, T cell proliferation, and T cell anti-cancer activity. A novel 'Personalized Adoptive Neuro-Immunotherapy' was invented for Ex vivo rejuvenation and empowerment of patient’s exhausted peripheral T cells by physiological Neurotransmitters/Neuropeptides, and their repeated infusion to patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Empowering exhausted T cells of Glioblastoma patients by Neurotransmitters and Neuropeptides: decreasing immune checkpoint inhibitors, and increasing CD3zeta, proliferation and Glioblastoma arrest

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Mia Levite,
  • Nili Ilouz,
  • Eithan Galun,
  • Yigal Shoshan

摘要

Background

Glioblastoma is the most common malignant brain tumor, with extremely poor prognosis, and patient’s T cells are exhausted, dysfunctional, and unable to eliminate Glioblastoma. To our knowledge, there is no effective and safe treatment for rejuvenating and improving multiple functions of exhausted T cells. We previously found that specific Neurotransmitters and Neuropeptides induce direct, potent and beneficial effects on human T cells.

Method

We studied if Dopamine, Glutamate, GnRH-II, Neuropeptide Y or their combinations, can rejuvenate and improve peripheral T cells of four Glioblastoma patients.

Results

The Glioblastoma patients had abnormally low numbers of T cells, and mostly small T cells. Single Ex-vivo treatment (24 h) of Glioblastoma patient’s T cells with either Dopamine, Glutamate, GnRH-II, or Neuropeptide Y, or their combinations (10−8 M, without any antigen/mitogen/cytokine/growth factor), induced multiple beneficial effects: 1. increased the number of live T cells; 2. decreased simultaneously all tested exhaustion-related immune checkpoint inhibitors: PD-1, Tim-3, LAG-3, TIGIT and CD160; 3. increased expression of TCR-associated CD3zeta; 4. increased proliferation of patient’s T cells in response to human Glioblastoma cells; and 5. dramatically increased arrest of Glioblastoma cells by Glioblastoma patient’s T cells.

Conclusions

Dopamine, Glutamate, Neuropeptide Y or GnRH-II, and the most beneficial being Dopamine + Neuropeptide Y, and Glutamate + Neuropeptide Y, can rejuvenate and improve Glioblastoma patient’s T cells. They simultaneously decrease multiple immune checkpoint imhibitory receptors, and increase CD3zeta, T cell proliferation, and T cell anti-cancer activity. A novel 'Personalized Adoptive Neuro-Immunotherapy' was invented for Ex vivo rejuvenation and empowerment of patient’s exhausted peripheral T cells by physiological Neurotransmitters/Neuropeptides, and their repeated infusion to patients.